PBS Snapshot – Cancer generics to suffer in October


Pharma in Focus
 & Mercurial report PBS price cuts due in October will attack one of the last remaining areas in which generic companies have been able to increase their income from the PBS over the last year: cancer drugs. For more on this article click here.

In more news, anti-epilepsy drug levetiractem, formerly UCB’s Keppra, is the fastest-growing generic among the top 100 off-patent drugs on the PBS based on script numbers, with a growth rate of 22 percent. Further insights on the leading generics in the Australian market can be found here.

Analytics for these pharma in focus stories were generated using MiPortal, Mercurial’s cloud-based business intelligence & analytics platform.

Click here for a free trial or contact Regan McCracken – Director – Commercial Effectiveness, on 02 8705 8754.

About Pharma in Focus

Pharma in Focus (PIF) is Australia’s premier independent pharma industry news service.

PIF deliver up-to-date, in-depth news coverage, analysis and opinion straight to your desktop each working day of the week, covering the whole pharma sector, both prescription and non-prescription in Australia and New Zealand.